Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “
Several other equities research analysts also recently issued reports on the company. Leerink Swann began coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued a “market perform” rating and a $24.00 price target on the stock. J P Morgan Chase & Co began coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Jefferies Group LLC began coverage on Dova Pharmaceuticals in a research report on Monday, July 24th. They issued a “buy” rating and a $30.00 price target on the stock.
Dova Pharmaceuticals (DOVA) traded up $1.79 during trading on Tuesday, reaching $24.92. 38,500 shares of the company’s stock traded hands, compared to its average volume of 125,397. Dova Pharmaceuticals has a 52-week low of $16.98 and a 52-week high of $29.99.
Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Thursday, November 9th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). During the same period in the previous year, the business earned ($0.41) EPS. equities analysts anticipate that Dova Pharmaceuticals will post -1.4 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Dova Pharmaceuticals, Inc. (DOVA) Downgraded by Zacks Investment Research” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://sportsperspectives.com/2017/11/14/dova-pharmaceuticals-inc-dova-downgraded-by-zacks-investment-research.html.
In other Dova Pharmaceuticals news, Director Paul B. Manning purchased 25,870 shares of the stock in a transaction dated Wednesday, August 16th. The shares were bought at an average cost of $22.30 per share, with a total value of $576,901.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in shares of Dova Pharmaceuticals in the second quarter valued at about $43,969,000. Perceptive Advisors LLC lifted its stake in shares of Dova Pharmaceuticals by 2.8% in the third quarter. Perceptive Advisors LLC now owns 1,754,015 shares of the company’s stock valued at $42,587,000 after buying an additional 47,516 shares during the period. Fosun International Ltd lifted its stake in shares of Dova Pharmaceuticals by 9.2% in the third quarter. Fosun International Ltd now owns 710,000 shares of the company’s stock valued at $17,239,000 after buying an additional 60,000 shares during the period. Paulson & CO. Inc. bought a new stake in shares of Dova Pharmaceuticals in the second quarter valued at about $13,856,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Dova Pharmaceuticals by 62.1% in the third quarter. Wells Fargo & Company MN now owns 324,287 shares of the company’s stock valued at $7,874,000 after buying an additional 124,287 shares during the period. Institutional investors and hedge funds own 23.67% of the company’s stock.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.